<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00631137</url>
  </required_header>
  <id_info>
    <org_study_id>J0634</org_study_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>JHOC-J0634</secondary_id>
    <secondary_id>NA_00003125</secondary_id>
    <secondary_id>CDR0000584274</secondary_id>
    <nct_id>NCT00631137</nct_id>
  </id_info>
  <brief_title>Testosterone Gel in Preventing Weakness Caused by Steroid Therapy in Men With Glioma</brief_title>
  <official_title>A Randomized, Controlled Comparative Trial to Determine if Testosterone Gel Prevents Steroid Related Weakness in Brain Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <brief_summary>
    <textblock>
      RATIONALE: Testosterone gel may be effective in preventing or lessening muscle weakness
      caused by steroid therapy in men receiving glucocorticoids for newly diagnosed high-grade
      glioma.

      PURPOSE: This randomized clinical trial is studying how well testosterone gel works in
      preventing weakness caused by steroid therapy in men receiving glucocorticoids for newly
      diagnosed high-grade glioma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To determine if daily administration of testosterone gel can prevent the development or
           reduce the severity of muscle weakness in men receiving glucocorticoids for newly
           diagnosed high-grade glioma.

      Secondary

        -  To compare the difference in percent change from baseline timed functional tests (TFT)
           between patients who are treated with testosterone gel and those who are not.

        -  To compare the difference in percent change from baseline activities of daily living as
           assessed by the Health Assessment Questionnaire-Disability Index (HAQ-DI) between
           patients who are treated with testosterone gel and those who are not.

        -  To compare the difference in percent change from baseline leg muscle mass as assessed by
           CT scan imaging between patients who are treated with testosterone gel and those who are
           not.

        -  To estimate the side effects of testosterone gel in these patients.

      OUTLINE: Patients are stratified according to daily glucocorticoid dose (&lt; 16 mg/day vs ≥ 16
      mg/day), Karnofsky performance status (≤ 80% vs &gt; 80%), and age (≤ 50 years of age vs &gt; 50
      years of age). Patients are randomized to 1 of 2 treatment arms.

        -  Arm I (control): Patients receive oral whey protein powder once daily for 7 months.

        -  Arm II (treatment): Patients apply topical testosterone gel to the shoulder, upper
           chest, or forearm once daily for 7 months.

      Patients undergo strength testing and functional testing (TFT) and complete an activities of
      daily living questionnaire at baseline and at 1, 3, 5, and 7 months. Patients also undergo CT
      scan of the leg and laboratory testing at baseline and at 3 and 7 months. Testosterone levels
      are obtained at baseline and at 1, 3, and 7 months.

      Patients complete a daily log of their glucocorticoid dose and to affirm compliance with
      therapy. Major clinical events related to underlying tumor (i.e., surgery, radiotherapy,
      initiating chemotherapy, concurrent antiepileptic therapy, deep vein thrombosis, pulmonary
      embolism, transfusions, seizures, pneumonia, and other forms of infection) are also recorded.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated due to low accrual.
  </why_stopped>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Event, Defined as ≥ 50% Loss of Strength in the Hip Flexors as Assessed by Dynamometry Peak Force Measures at Baseline and at 1, 3, 5, and 7 Months</measure>
    <time_frame>baseline and at 1, 3, 5, and 7 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Muscle Strength Testing in Other Proximal Muscles (i.e., Knee Extensors, Knee Flexors, Arm Abductors, Elbow Extensors and Flexors, and Neck Flexors) as Assessed by Dynamometry at Baseline and at 1, 3, 5, and 7 Months</measure>
    <time_frame>baseline and at 1, 3, 5, and 7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance on Timed Functional Tests (TFT) as Assessed at Baseline and at 1, 3, 5, and 7 Months</measure>
    <time_frame>baseline and at 1, 3, 5, and 7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leg Muscle Mass as Assessed by CT Scan at Baseline and at 3 and 7 Months</measure>
    <time_frame>baseline and at 3 and 7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activities of Daily Living as Assessed by the Health Assessment Questionnaire-Disability Index at Baseline and at 1, 3, 5, and 7 Months</measure>
    <time_frame>baseline and at 1, 3, 5, and 7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effects of Testosterone Gel as Assessed by Frequency of Adverse Events, Including Laboratory Abnormalities</measure>
    <time_frame>while receiving treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Total Testosterone Levels as Assessed at Baseline and at 1, 3, and 7 Months</measure>
    <time_frame>baseline and at 1, 3, and 7</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Musculoskeletal Complications</condition>
  <arm_group>
    <arm_group_label>Arm 1: Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>whey protein powder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM 2 : Treatment Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Testosterone Gel (10g pouch/day) applied to skin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>testosterone gel applied to skin</intervention_name>
    <description>Application of testosterone gel</description>
    <arm_group_label>ARM 2 : Treatment Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>whey powder protein</intervention_name>
    <arm_group_label>Arm 1: Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Newly diagnosed high-grade glioma, including the following subtypes:

               -  Anaplastic astrocytoma

               -  Anaplastic oligodendroglioma

               -  Glioblastoma multiforme

          -  Requires dexamethasone at a dose of &gt; 4 mg/day to control symptoms of tumor-related
             edema at time of study enrollment AND has been on a stable dose of steroids for ≥ 5
             days prior to study enrollment

          -  Completed ≥ 80% of prescribed radiotherapy

          -  Hypogonadal, defined as serum testosterone level &lt; 350 ng/dL

          -  No history of prostate or breast cancer

          -  No benign prostatic hypertrophy requiring therapy OR AUA score of ≥ 8

               -  PSA ≤ 4 ng/mL

        PATIENT CHARACTERISTICS:

          -  Karnofsky performance status 60-100%

          -  Able to keep daily records or has a care provider that agrees to keep daily records of
             drug administration

          -  No clinical history of congestive heart failure requiring therapy

          -  No psychotic disorder requiring active treatment

          -  No structured exercise program involving exercise for &gt; 3 hours/week

          -  No polycythemia (i.e., hematocrit &gt; 52%)

        PRIOR CONCURRENT THERAPY:

          -  More than 6 months since prior androgen therapy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaishri O. Blakeley, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>March 6, 2008</study_first_submitted>
  <study_first_submitted_qc>March 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2008</study_first_posted>
  <results_first_submitted>March 1, 2013</results_first_submitted>
  <results_first_submitted_qc>August 24, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 27, 2018</results_first_posted>
  <last_update_submitted>August 24, 2018</last_update_submitted>
  <last_update_submitted_qc>August 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>musculoskeletal complications</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>outpatient clinic</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>ARM 2 : Treatment Group</title>
          <description>Androgel (10g pouch/day)
testosterone gel :
questionnaire administration :</description>
        </group>
        <group group_id="P2">
          <title>Arm 1: Control Group</title>
          <description>whey protein powder
questionnaire administration :</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>No participants were assigned to the Control Group Arm</population>
      <group_list>
        <group group_id="B1">
          <title>ARM 2 : Treatment Group</title>
          <description>Androgel (10g pouch/day)
testosterone gel :
questionnaire administration :</description>
        </group>
        <group group_id="B2">
          <title>Arm 1: Control Group</title>
          <description>whey protein powder
questionnaire administration :</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Event, Defined as ≥ 50% Loss of Strength in the Hip Flexors as Assessed by Dynamometry Peak Force Measures at Baseline and at 1, 3, 5, and 7 Months</title>
        <time_frame>baseline and at 1, 3, 5, and 7 months</time_frame>
        <population>Only 1 subject accrued. Not enough data to analysis</population>
        <group_list>
          <group group_id="O1">
            <title>ARM 2 : Treatment Group</title>
            <description>Androgel (10g pouch/day)
testosterone gel :
questionnaire administration :</description>
          </group>
          <group group_id="O2">
            <title>Arm 1: Control Group</title>
            <description>whey protein powder
questionnaire administration :</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Event, Defined as ≥ 50% Loss of Strength in the Hip Flexors as Assessed by Dynamometry Peak Force Measures at Baseline and at 1, 3, 5, and 7 Months</title>
          <population>Only 1 subject accrued. Not enough data to analysis</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Muscle Strength Testing in Other Proximal Muscles (i.e., Knee Extensors, Knee Flexors, Arm Abductors, Elbow Extensors and Flexors, and Neck Flexors) as Assessed by Dynamometry at Baseline and at 1, 3, 5, and 7 Months</title>
        <time_frame>baseline and at 1, 3, 5, and 7 months</time_frame>
        <population>Only 1 subject accrued. Not enough data to analysis</population>
        <group_list>
          <group group_id="O1">
            <title>ARM 2 : Treatment Group</title>
            <description>Androgel (10g pouch/day)
testosterone gel :
questionnaire administration :</description>
          </group>
          <group group_id="O2">
            <title>Arm 1: Control Group</title>
            <description>whey protein powder
questionnaire administration :</description>
          </group>
        </group_list>
        <measure>
          <title>Muscle Strength Testing in Other Proximal Muscles (i.e., Knee Extensors, Knee Flexors, Arm Abductors, Elbow Extensors and Flexors, and Neck Flexors) as Assessed by Dynamometry at Baseline and at 1, 3, 5, and 7 Months</title>
          <population>Only 1 subject accrued. Not enough data to analysis</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Performance on Timed Functional Tests (TFT) as Assessed at Baseline and at 1, 3, 5, and 7 Months</title>
        <time_frame>baseline and at 1, 3, 5, and 7 months</time_frame>
        <population>Only 1 subject accrued. Not enough data to analysis</population>
        <group_list>
          <group group_id="O1">
            <title>ARM 2 : Treatment Group</title>
            <description>Androgel (10g pouch/day)
testosterone gel :
questionnaire administration :</description>
          </group>
          <group group_id="O2">
            <title>Arm 1: Control Group</title>
            <description>whey protein powder
questionnaire administration :</description>
          </group>
        </group_list>
        <measure>
          <title>Performance on Timed Functional Tests (TFT) as Assessed at Baseline and at 1, 3, 5, and 7 Months</title>
          <population>Only 1 subject accrued. Not enough data to analysis</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Leg Muscle Mass as Assessed by CT Scan at Baseline and at 3 and 7 Months</title>
        <time_frame>baseline and at 3 and 7 months</time_frame>
        <population>Only 1 subject accrued. Not enough data to analysis</population>
        <group_list>
          <group group_id="O1">
            <title>ARM 2 : Treatment Group</title>
            <description>Androgel (10g pouch/day)
testosterone gel :
questionnaire administration :</description>
          </group>
          <group group_id="O2">
            <title>Arm 1: Control Group</title>
            <description>whey protein powder
questionnaire administration :</description>
          </group>
        </group_list>
        <measure>
          <title>Leg Muscle Mass as Assessed by CT Scan at Baseline and at 3 and 7 Months</title>
          <population>Only 1 subject accrued. Not enough data to analysis</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Activities of Daily Living as Assessed by the Health Assessment Questionnaire-Disability Index at Baseline and at 1, 3, 5, and 7 Months</title>
        <time_frame>baseline and at 1, 3, 5, and 7 months</time_frame>
        <population>only 1 subject enrolled. Not enough to do analysis</population>
        <group_list>
          <group group_id="O1">
            <title>ARM 2 : Treatment Group</title>
            <description>Androgel (10g pouch/day)
testosterone gel :
questionnaire administration :</description>
          </group>
          <group group_id="O2">
            <title>Arm 1: Control Group</title>
            <description>whey protein powder
questionnaire administration :</description>
          </group>
        </group_list>
        <measure>
          <title>Activities of Daily Living as Assessed by the Health Assessment Questionnaire-Disability Index at Baseline and at 1, 3, 5, and 7 Months</title>
          <population>only 1 subject enrolled. Not enough to do analysis</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effects of Testosterone Gel as Assessed by Frequency of Adverse Events, Including Laboratory Abnormalities</title>
        <time_frame>while receiving treatment</time_frame>
        <population>only 1 subject enrolled. Not enough to do analysis</population>
        <group_list>
          <group group_id="O1">
            <title>ARM 2 : Treatment Group</title>
            <description>Androgel (10g pouch/day)
testosterone gel :
questionnaire administration :</description>
          </group>
          <group group_id="O2">
            <title>Arm 1: Control Group</title>
            <description>whey protein powder
questionnaire administration :</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effects of Testosterone Gel as Assessed by Frequency of Adverse Events, Including Laboratory Abnormalities</title>
          <population>only 1 subject enrolled. Not enough to do analysis</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Total Testosterone Levels as Assessed at Baseline and at 1, 3, and 7 Months</title>
        <time_frame>baseline and at 1, 3, and 7</time_frame>
        <population>only 1 subject enrolled. Not enough to do analysis</population>
        <group_list>
          <group group_id="O1">
            <title>ARM 2 : Treatment Group</title>
            <description>Androgel (10g pouch/day)
testosterone gel :
questionnaire administration :</description>
          </group>
          <group group_id="O2">
            <title>Arm 1: Control Group</title>
            <description>whey protein powder
questionnaire administration :</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Total Testosterone Levels as Assessed at Baseline and at 1, 3, and 7 Months</title>
          <population>only 1 subject enrolled. Not enough to do analysis</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>through study completion, up to 1 year</time_frame>
      <desc>The definition of adverse event and/or serious adverse event does not differ from the clinicaltrials.gov definition.</desc>
      <group_list>
        <group group_id="E1">
          <title>ARM 2 : Treatment Group</title>
          <description>Androgel (10g pouch/day)
testosterone gel :
questionnaire administration :</description>
        </group>
        <group group_id="E2">
          <title>Arm 1: Control Group</title>
          <description>whey protein powder
questionnaire administration :</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash: acne/acneiform</sub_title>
                <description>grade 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>early termination, leading to only 1 subject enrolled, hence could NOT do data analysis</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jaishri Blakeley</name_or_title>
      <organization>Johns Hopkins</organization>
      <phone>410-955-8837</phone>
      <email>jblakel3@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

